First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: Françoise Kraeber-Bodéré Udai Banerji Jean-Charles Soria Saoirse Dolly |
| Publication date | July 3, 2012 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |